title: Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation.
authors: Hugues
authors: H
authors: de Lavallade
authors: Jamshid S
authors: JS
authors: Khorashad
authors: Howard P
authors: HP
authors: Davis
authors: Dragana
authors: D
authors: Milojkovic
authors: Jaspal S
authors: JS
authors: Kaeda
authors: John M
authors: JM
authors: Goldman
authors: Jane F
authors: JF
authors: Apperley
authors: David
authors: D
authors: Marin
mesh_terms: D000368:Aged; D016044:Fusion Proteins, bcr-abl / Q000235:genetics* / Q000378:metabolism; D006248:Harringtonines / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D007532:Isoleucine / Q000235:genetics / Q000378:metabolism; D007700:Kinetics; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000188:drug therapy* / Q000235:genetics*; D008297:Male; D009154:Mutation / Q000235:genetics*; D016879:Salvage Therapy; D014443:Tyrosine / Q000235:genetics / Q000378:metabolism
chemical_list: D006248:Harringtonines; D016898:Interferon-alpha; D007532:Isoleucine; D014443:Tyrosine; D000077863:Homoharringtonine; D016044:Fusion Proteins, bcr-abl